{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:44:36Z","timestamp":1793036676343,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02853-6","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:54:28Z","timestamp":1779778468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"21","author":[{"given":"David","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ealia","family":"Khoshkish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Jomy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Y.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"1","key":"2853_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. JCO. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"JCO"},{"issue":"6","key":"2853_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2011.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"2853_CR3","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow SGaede SLouie AVHaasbeek CMulroy L, et al. Stereotactic Ablative radiotherapy for the comprehensive treatment of oligometastatic Cancers: long-term results of the SABR-COMET phase II randomized trial. JCO. 2020;38(25):2830\u201338. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"JCO"},{"issue":"5","key":"2853_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u201359. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2853_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, Multicenter phase II trial. JCO. 2018;36(5):446\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"JCO"},{"key":"2853_CR6","doi-asserted-by":"publisher","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non\u2013small-Cell lung cancer. JAMA Oncol. 2018;4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","DOI":"10.1001\/jamaoncol.2017.3501"},{"issue":"18","key":"2853_CR7","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non\u2013small-Cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. JCO. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"JCO"},{"issue":"16_suppl","key":"2853_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). JCO. 2022;40(16_suppl):1007\u20131007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1007.","journal-title":"JCO"},{"issue":"29","key":"2853_CR9","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van Der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. JCO. 2022;40(29):3377\u201382. https:\/\/doi.org\/10.1200\/JCO.22.00644.","journal-title":"JCO"},{"issue":"6_suppl","key":"2853_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","volume":"38","author":"P Ost","year":"2020","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial. JCO. 2020;38(6_suppl):10\u201310. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.10.","journal-title":"JCO"},{"issue":"10422","key":"2853_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3.","journal-title":"Lancet"},{"issue":"7109","key":"2853_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"2","key":"2853_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-Plot\u2013Based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363. https:\/\/doi.org\/10.1111\/j.0006-341X.2000.00455.x.","journal-title":"Biometrics"},{"issue":"7650","key":"2853_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u201326. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"2853_CR15","doi-asserted-by":"publisher","unstructured":"Francolini G, Detti B, Di Cataldo V, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO - NCT03449719). Eur Urol Open Sci. 2023;57:S157\u201358. https:\/\/doi.org\/10.1016\/S2666-1683(23)01401-5.","DOI":"10.1016\/S2666-1683(23)01401-5"},{"issue":"36","key":"2853_CR16","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body Radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). JCO. 2023;41(36):5561\u201368. https:\/\/doi.org\/10.1200\/JCO.23.00985.","journal-title":"JCO"},{"issue":"6_suppl","key":"2853_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2021.39.6_suppl.118","volume":"39","author":"G Francolini","year":"2021","unstructured":"Francolini G, Garlatti P, Loi M, et al. ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis. J Clin Oncol. 2021;39(6_suppl):118\u2013118. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.118.","journal-title":"J Clin Oncol"},{"key":"2853_CR18","doi-asserted-by":"publisher","unstructured":"Khoo V, Kirby A, Ahmed M, Dewan M, Van as N, Franks K, et al. OC-0761 CORE - Standard of care +\/- stereotactic body radiotherapy for oligometastases - primary results. Radiother Oncol. 2023;182:S627. https:\/\/doi.org\/10.1016\/S0167-8140(23)08702-9.","DOI":"10.1016\/S0167-8140(23)08702-9"},{"issue":"5","key":"2853_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.09.008","volume":"114","author":"CJ Tsai","year":"2022","unstructured":"Tsai CJ, Yang JT, Guttmann DM, Shaverdian N, Eng J, Yeh R, et al. Final analysis of Consolidative use of radiotherapy to block (CURB) oligoprogression trial - a randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast Cancers. Int J Multiling Radiat Oncol*Biol*Phys. 2022;114(5):1061. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.008.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"5","key":"2853_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ijrobp.2021.09.014","volume":"111","author":"CJ Tsai","year":"2021","unstructured":"Tsai CJ, Yang JT, Guttmann DM, Shaverdian N, Shepherd AF, Eng J, et al. Consolidative use of radiotherapy to block (CURB) oligoprogression \u2015 interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic Cancers of the lung and breast. Int J Multiling Radiat Oncol*Biol*Phys. 2021;111(5):1325\u201326. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.014.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"1","key":"2853_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","volume":"9","author":"Q Liu","year":"2024","unstructured":"Liu Q, Chen J, Lin Y, Ye J, Shen W, Luo H, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. LancetThe Lancet Gastroenterol Hepatol. 2024;9(1):45\u201355. https:\/\/doi.org\/10.1016\/S2468-1253(23)00316-3.","journal-title":"LancetThe Lancet Gastroenterol Hepatol"},{"issue":"32","key":"2853_CR22","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, et al. Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a Multicenter, randomized phase II trial. JCO. 2024;42(32):3795\u2013805. https:\/\/doi.org\/10.1200\/JCO.24.00081.","journal-title":"JCO"},{"issue":"4","key":"2853_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","volume":"121","author":"JP Reddy","year":"2025","unstructured":"Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, et al. Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a Multicenter, randomized phase 2 trial. Int J Multiling Radiat Oncol*Biol*Phys. 2025;121(4):885\u201393. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.10.030.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"6","key":"2853_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9(6):825. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0161.","journal-title":"JAMA Oncol"},{"issue":"5_suppl","key":"2853_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","volume":"43","author":"T Niazi","year":"2025","unstructured":"Niazi T, Saad F, Koul R, Thibault I, Chung PWM, Wakil G, et al. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: a randomized phase II trial (GROUQ-PCS 9). JCO. 2025;43(5_suppl):22\u201322. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.22.","journal-title":"JCO"},{"issue":"3","key":"2853_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","volume":"110","author":"MJ Zelefsky","year":"2021","unstructured":"Zelefsky MJ, Yamada Y, Greco C, Lis E, Sch\u00f6der H, Lobaugh S, et al. Phase 3 multi-center, prospective, randomized trial Comparing Single-dose 24 Gy Radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer. Int J Multiling Radiat Oncol*Biol*Phys. 2021;110(3):672\u201379. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.004.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"12","key":"2853_CR27","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0.","journal-title":"The Lancet Oncol"},{"key":"2853_CR28","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184:109681. https:\/\/doi.org\/10.1016\/j.radonc.2023.109681.","journal-title":"Radiother Oncol"},{"issue":"10","key":"2853_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study Comparing Prophylactic Cranial Irradiation alone to Prophylactic Cranial Irradiation and Consolidative extracranial Irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12(10):1561\u201370. https:\/\/doi.org\/10.1016\/j.jtho.2017.06.015.","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"2853_CR30","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Hu C, Gomez DR, Timmerman RD, Simone CB, Robinson CG, et al. NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). JCO. 2024;42(16_suppl):8506\u20138506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8506.","journal-title":"JCO"},{"key":"2853_CR31","doi-asserted-by":"publisher","unstructured":"Thariat J, Bosset M, Falcoz A, Vernerey D, Pointreau Y, Racadot S, et al. 853O OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1\u20133 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014\u201304 \u201cOMET\u201d randomized phase II trial. Ann Oncol. 2023;34:S554. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1999.","DOI":"10.1016\/j.annonc.2023.09.1999"},{"issue":"5","key":"2853_CR32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.ijrobp.2024.11.084","volume":"121","author":"J Thariat","year":"2025","unstructured":"Thariat J, Bosset M, Falcoz A, Vernerey D, Pointreau Y, Racadot S, et al. Survival without quality of Life deterioration in the GORTEC 2014\u201304 \u201cOMET\u201d randomized phase 2 trial in patients with head and neck cancer with oligometastases using stereotactic Ablative Radiation therapy (SABR) alone or chemotherapy and SABR. Int J Multiling Radiat Oncol*Biol*Phys. 2025;121(5):1194\u2013206. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.084.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"3","key":"2853_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. The Lancet Oncol. 2025;26(3):300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00730-7.","journal-title":"The Lancet Oncol"},{"issue":"4","key":"2853_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Multiling Radiat Oncol*Biol*Phys. 2022;114(4):611\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"18","key":"2853_CR35","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO-25-00131","volume":"43","author":"JH Wang","year":"2025","unstructured":"Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, et al. Outcomes of radium-223 and stereotactic Ablative radiotherapy versus stereotactic Ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial. JCO. 2025;43(18):2059\u201368. https:\/\/doi.org\/10.1200\/JCO-25-00131.","journal-title":"JCO"},{"issue":"6","key":"2853_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, Yu R-L, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR -mutated non-small cell lung cancer. JNCI: J Natl Cancer Inst. 2023;115(6):742\u201348. https:\/\/doi.org\/10.1093\/jnci\/djac015.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"2853_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","volume":"121","author":"D Schellenberg","year":"2025","unstructured":"Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, et al. Stereotactic Ablative Radiation for oligoprogressive Cancers: results of the randomized phase 2 STOP trial. Int J Multiling Radiat Oncol*Biol*Phys. 2025;121(1):28\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.031.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"10","key":"2853_CR38","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","volume":"7","author":"S Siva","year":"2021","unstructured":"Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, et al. Single-fraction vs multifraction stereotactic Ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans Tasman Radiation Oncology group 13.01 phase 2 randomized clinical trial. JAMA Oncol. 2021;7(10):1476. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2939.","journal-title":"JAMA Oncol"},{"key":"2853_CR39","doi-asserted-by":"publisher","unstructured":"Siva S, Sakyanun P, Mai T, Wong W, Lim A, Ludbrook J, et al. OC-0610 long-term outcomes of TROG13.01 SAFRON II: single vs multi-fraction SABR for oligometastases to lung. Radiother Oncol. 2023;182:S494\u201395. https:\/\/doi.org\/10.1016\/S0167-8140(23)08666-8.","DOI":"10.1016\/S0167-8140(23)08666-8"},{"issue":"5_suppl","key":"2853_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2025.43.5_suppl.160","volume":"43","author":"G Francolini","year":"2025","unstructured":"Francolini G, Di Cataldo V, Garlatti P, Caini S, Bruni A, Simoni N, et al. PERSIAN trial: early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. JCO. 2025;43(5_suppl):160\u2013160. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.160.","journal-title":"JCO"},{"issue":"1","key":"2853_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. https:\/\/doi.org\/10.1186\/s12885-019-5977-6.","journal-title":"BMC Cancer"},{"issue":"5","key":"2853_CR42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","volume":"50","author":"DC Wedge","year":"2018","unstructured":"CAMCAP Study Group, The TCGA Consortium, Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50(5):682\u201392. https:\/\/doi.org\/10.1038\/s41588-018-0086-z.","journal-title":"Nat Genet"},{"issue":"2","key":"2853_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/PPO.0000000000000434","volume":"26","author":"CC Foster","year":"2020","unstructured":"Foster CC, Pitroda SP, Weichselbaum RR. Definition, biology, and history of oligometastatic and oligoprogressive disease. Cancer J. 2020;26(2):96\u201399. https:\/\/doi.org\/10.1097\/PPO.0000000000000434.","journal-title":"Cancer J"},{"issue":"4","key":"2853_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijrobp.2022.08.027","volume":"114","author":"H Kim","year":"2022","unstructured":"Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, et al. Local therapy for oligoprogressive disease: a systematic review of prospective trials. Int J Multiling Radiat Oncol*Biol*Phys. 2022;114(4):676\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.027.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"7","key":"2853_CR45","doi-asserted-by":"publisher","first-page":"101797","DOI":"10.1016\/j.adro.2025.101797","volume":"10","author":"Y Berner-Wygoda","year":"2025","unstructured":"Berner-Wygoda Y, Amir E, Blumenfeld P, Li M, Malon D, Pathak N, et al. Efficacy and safety of metastatic directed treatment of oligometastatic disease: results of a meta-analysis. Adv Radiat Oncol. 2025;10(7):101797. https:\/\/doi.org\/10.1016\/j.adro.2025.101797.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"2853_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update. JCO. 2019;37(5):423\u201338. https:\/\/doi.org\/10.1200\/JCO.18.01160.","journal-title":"JCO"},{"issue":"2","key":"2853_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PPO.0000000000000438","volume":"26","author":"KJ Barnum","year":"2020","unstructured":"Barnum KJ, Weiss SA. Prognostic and predictive Biomarkers in oligometastatic disease. Cancer J. 2020;26(2):100\u201307. https:\/\/doi.org\/10.1097\/PPO.0000000000000438.","journal-title":"Cancer J"},{"issue":"2","key":"2853_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PPO.0000000000000437","volume":"26","author":"DM Routman","year":"2020","unstructured":"Routman DM, Chera BS, Gupta GP. Circulating tumor DNA Biomarkers for early detection of Oligometastasis. Cancer J. 2020;26(2):116\u201323. https:\/\/doi.org\/10.1097\/PPO.0000000000000437.","journal-title":"Cancer J"},{"issue":"1","key":"2853_CR49","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1038\/s41598-025-88266-z","volume":"15","author":"R Radigan","year":"2025","unstructured":"Radigan R, Kao CS, Krainock M, Liu MC, Gupta V, Alexander L, et al. Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases. Sci Rep. 2025;15(1):6126. https:\/\/doi.org\/10.1038\/s41598-025-88266-z.","journal-title":"Sci Rep"},{"issue":"12","key":"2853_CR50","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/s1470-2045(24)00596-5","volume":"25","author":"R Forrest","year":"2024","unstructured":"Forrest R, Lagarde M, Aggarwal A, Naci H. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol. 2024;25(12):1635\u201343. https:\/\/doi.org\/10.1016\/s1470-2045(24)00596-5.","journal-title":"The Lancet Oncol"},{"issue":"12","key":"2853_CR51","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jval.2023.08.009","volume":"26","author":"ASJ Yong","year":"2023","unstructured":"Yong ASJ, Lim KK, Fox-Rushby J, Ismail F, Hamzah E, Cheong MWL, et al. A longitudinal evaluation of the preferences of patients with advanced cancer for quality of Life and survival in Malaysia: a discrete choice experiment. Value Health. 2023;26(12):1772\u201381. https:\/\/doi.org\/10.1016\/j.jval.2023.08.009.","journal-title":"Value Health"},{"key":"2853_CR52","doi-asserted-by":"publisher","unstructured":"Zhang M, He X, Wu J, Xie F. Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer. 2023;23(1). https:\/\/doi.org\/10.1186\/s12885-023-11598-4.","DOI":"10.1186\/s12885-023-11598-4"},{"key":"2853_CR53","doi-asserted-by":"publisher","unstructured":"Willmann J, von Wachter C, Zehnder R, Dee EC, Chen H, Hendriks LEL, et al. Stereotactic body radiotherapy without systemic therapy for oligometastatic cancer: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(12):e2549685. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49685.","DOI":"10.1001\/jamanetworkopen.2025.49685"},{"issue":"3","key":"2853_CR54","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.02.019","volume":"108","author":"SI Gutiontov","year":"2020","unstructured":"Gutiontov SI, Pitroda SP, Weichselbaum RR. Oligometastasis: past, present, future. Int J Multiling Radiat Oncol*Biol*Phys. 2020;108(3):530\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.02.019.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"5","key":"2853_CR55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ijrobp.2022.07.012","volume":"114","author":"AS Barry","year":"2022","unstructured":"Barry AS, Bezjak A, Helou J, Goodwin P, Kiss A, Ringash J, et al. The impact of disease progression on health-related quality of Life outcomes in patients with oligometastatic disease at 12 months post stereotactic body Radiation therapy. Int J Multiling Radiat Oncol*Biol*Phys. 2022;114(5):989\u201399. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.012.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"key":"2853_CR56","doi-asserted-by":"publisher","first-page":"667993","DOI":"10.3389\/fonc.2021.667993","volume":"11","author":"D Mehrens","year":"2021","unstructured":"Mehrens D, Unterrainer M, Corradini S, Niyazi M, Manapov F, Westphalen CB, et al. Cost-effectiveness analysis of local treatment in oligometastatic disease. Front Oncol. 2021;11:667993. https:\/\/doi.org\/10.3389\/fonc.2021.667993.","journal-title":"Front Oncol"},{"key":"2853_CR57","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.ctro.2024.100838","volume":"48","author":"SM Christ","year":"2024","unstructured":"Christ SM, Breitenstein M, Heesen P, Turner B, Muehlematter UJ, Pohl K, et al. Clinical management of oligometastatic cancer: applying multidisciplinary tumor board recommendations in practice. Clin Transl Radiat Oncol. 2024;48:100838. https:\/\/doi.org\/10.1016\/j.ctro.2024.100838.","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02853-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:49:59Z","timestamp":1784598599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02853-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2853"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02853-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"97"}}